UNION therapeutics A/S completes dosing of healthy volunteers with UNI911 (inhaled niclosamide) for COVID-19

·UNION has successfully completed inhalation dosing of 44 healthy volunteers, confirming the safety and tolerability of UNI911 · UNION has utilized many years of experience with niclosamide to develop UNI911, a proprietary salt form and formulation of niclosamide, for inhalation as a treatment candidate for COVID-19 · Delivery directly to the lung via inhalation allows UNION to address common challenges related to low bioavailability of oral niclosamide · Niclosamide has been identified as a potent inhibitor of SARS-Cov-2 by Institut Pasteur Korea, with potency >40x higher than